Tapinarof 1% QD was well tolerated and demonstrated rapid, clinically meaningful, and durable improvements in clinical efficacy in a high proportion of patients with psoriasis who did not achieve treatment targets with current systemic or biologic therapies.

**MATERIALS AND METHODS**

**OBJECTIVE**

To present analyses of treatment outcomes and measures of treatment success in three Phase 3 trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis.

**INTRODUCTION**

In clinical practice, many patients fail to meet treatment targets, and current topical treatments alone are generally insufficiently effective.

**Endpoints and Statistical Analysis**

Analyses of a large cohort of patients treated with systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register) have shown that achieving an absolute PASI total score of ≤2 corresponded to achievement of a 90% decrease in PASI score (PASI90).

**RESULTS**

Baseline Patient Demographics and Disease Characteristics

**TREATMENT OUTCOMES AND MEASURES OF TREATMENT SUCCESS IN THREE PHASE 3 TRIALS OF TAPINAROF CREAM 1% ONCE DAILY FOR MILD TO SEvere PLAQUE PSORIASIS**

<Continued text from page...>